Company
Embecta
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
2
510(k), De Novo and PMA
Device trials
1
As lead sponsor, any status
Adverse event reports
5,483
Received Nov 1, 2025 to Nov 19, 2026
Recall records
3
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Embecta, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Embecta.
Latest FDA decisions
K260208 · Decided Jul 13, 2026 · 171 days after receipt
Device type: Syringe, Piston (FMF) · Hospital Medicine & Nursing
K234027 · Decided Aug 30, 2024 · 254 days after receipt
Device type: Alternate Controller Enabled Insulin Infusion Pump (QFG) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Embecta AID System in Adults With Type 2 DiabetesPivotal-lookingWithdrawn
NCT06692153 · 0 participants · Start Jan 2025 · Primary completion Mar 2026
Device: An AID System. · For: Type 2 Diabetes; Type 2 Diabetes Mellitus (T2DM); Type 2 DM and 4 more
Sites: Palo Alto, California; Walnut Creek, California; Indianapolis, Indiana · 9 sites in all
Reports received
5,483
Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.
Malfunction reports
5,375
98% of reports
Injury reports
106
1.9% of reports
Death reports
1
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 1 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 59 | 3 | 0 | 0 |
| May 24 | 209 | 2 | 0 | 0 |
| Jun 24 | 159 | 6 | 0 | 0 |
| Jul 24 | 192 | 1 | 0 | 0 |
| Aug 24 | 158 | 3 | 0 | 0 |
| Sep 24 | 154 | 1 | 0 | 0 |
| Oct 24 | 149 | 0 | 0 | 0 |
| Nov 24 | 170 | 1 | 0 | 0 |
| Dec 24 | 164 | 5 | 0 | 0 |
| Jan 25 | 150 | 1 | 0 | 0 |
| Feb 25 | 141 | 0 | 0 | 0 |
| Mar 25 | 157 | 1 | 0 | 0 |
| Apr 25 | 131 | 4 | 0 | 0 |
| May 25 | 95 | 0 | 0 | 0 |
| Jun 25 | 56 | 0 | 0 | 0 |
| Jul 25 | 33 | 0 | 0 | 0 |
| Aug 25 | 38 | 0 | 0 | 0 |
| Sep 25 | 52 | 3 | 0 | 0 |
| Oct 25 | 16 | 1 | 0 | 0 |
| Nov 25 | 9 | 1 | 1 | 0 |
| Dec 25 | 9 | 1 | 0 | 0 |
| Jan 26 | 14 | 5 | 0 | 0 |
| Feb 26 | 14 | 1 | 0 | 0 |
| Mar 26 | 15 | 5 | 0 | 0 |
| Apr 26 | 16 | 3 | 0 | 0 |
| May 26 | 12 | 3 | 0 | 0 |
| Jun 26 | 27 | 8 | 0 | 0 |
| Jul 26 | 21 | 9 | 0 | 1 |
| Aug 26 | 17 | 17 | 0 | 0 |
| Sep 26 | 969 | 19 | 0 | 0 |
| Oct 26 | 4,252 | 34 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- Unknown251
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2424-2024 · Started Jun 18, 2024 · Posted by FDA Jul 23, 2024
Reason given: BD Nano 2nd Gen Pen Needle was shipped close to or after the labeled expiration date of February 29, 2024. Using a device past its expiry sterility and integrity of the device cannot be guaranteed.
Cause as FDA categorized it: Process control · Device type: Needle, Hypodermic, Single Lumen (FMI)
- EWO_02512 (Catalog number 320550) For Investigational Use Only Nano Pro Un-Cannulated Demo Samples Quantity 100Open, Classified
Z-3179-2026 · Started Jul 26, 2023 · Posted by FDA Sep 16, 2026
Reason given: Retrospectively reported: Pen needles labeled 'For Investigational Use Only' were inadvertently distributed as commercially marketed devices.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Needle, Hypodermic, Single Lumen (FMI)
- EWO_02513 (Catalog number 320122) For Investigational Use Only Nano Un-Cannulated Demo Samples Quantity 100Open, Classified
Z-3180-2026 · Started Jul 26, 2023 · Posted by FDA Sep 16, 2026
Reason given: Retrospectively reported: Pen needles labeled 'For Investigational Use Only' were inadvertently distributed as commercially marketed devices.
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Needle, Hypodermic, Single Lumen (FMI)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.